Description
MK-677 (Ibutamoren) 10 mg Driada Medical — ibutamoren (MK-677) from Driada Medical at 10 mg. Oral GH secretagogue mimicking ghrelin — pulsatile GH release following physiological rhythm rather than bolus injection.
Key Benefits
- Oral GH secretagogue — raises endogenous GH and IGF-1
- Sleep quality, appetite, recovery improvements
- Does not suppress HPTA
- Long-run compound — 3–6 month commitment for full effect
- Water retention common in first month
- Each unit dosed at 10 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: 10–25 mg/day, single oral dose pre-bed (sleep benefit) or split. Cycles 3–6 months for full recomposition effect.
How It Works
Ibutamoren, ghrelin-receptor agonist. Triggers endogenous GH pulse release from the pituitary, elevates IGF-1. Mechanism distinct from exogenous HGH — works on the physiological pulse pathway.
Pharmacokinetics
Plasma half-life approximately 24 hours. Single daily dose produces stable GH/IGF-1 elevation.
Potential Side Effects
Water retention first month (resolves). Insulin resistance risk on long runs — monitor fasting glucose. Appetite increase. Mild lethargy in a minority of users.
Cycle & Stacking Guide
3–6 month protocols. Stacks cleanly with SARMs or AAS cycles for recovery amplification. Store pills dry and cool.
Manufacturer Notes
Driada Medical positions itself at the affordable end of the market while maintaining third-party lab verification. Their vial caps carry a tamper-seal date code.
Storage & Handling
Store in the original blister or bottle at 15–25 °C, away from direct sunlight, heat, and humidity. Oral preparations lose potency faster if exposed to moisture; keep the desiccant (if included) with the tablets. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.